EVEREST MED.LTD DL-0001 - Asset Resilience Ratio
EVEREST MED.LTD DL-0001 (6HN) has an Asset Resilience Ratio of 12.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore EVEREST MED.LTD DL-0001 balance sheet assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how EVEREST MED.LTD DL-0001's Asset Resilience Ratio has changed over time. See EVEREST MED.LTD DL-0001 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down EVEREST MED.LTD DL-0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EVEREST MED.LTD DL-0001 stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €887.09 Million | 12.98% |
| Total Liquid Assets | €887.09 Million | 12.98% |
Asset Resilience Insights
- Moderate Liquidity: EVEREST MED.LTD DL-0001 has 12.98% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
EVEREST MED.LTD DL-0001 Industry Peers by Asset Resilience Ratio
Compare EVEREST MED.LTD DL-0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for EVEREST MED.LTD DL-0001 (2022–2025)
The table below shows the annual Asset Resilience Ratio data for EVEREST MED.LTD DL-0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.98% | €887.09 Million ≈ $1.04 Billion |
€6.83 Billion ≈ $7.99 Billion |
-1.52pp |
| 2024-12-31 | 14.50% | €718.84 Million ≈ $840.40 Million |
€4.96 Billion ≈ $5.80 Billion |
-17.15pp |
| 2023-12-31 | 31.64% | €1.83 Billion ≈ $2.14 Billion |
€5.77 Billion ≈ $6.75 Billion |
+14.10pp |
| 2022-12-31 | 17.55% | €1.16 Billion ≈ $1.36 Billion |
€6.61 Billion ≈ $7.73 Billion |
-- |
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocyc… Read more